IRIS UniCatt

Chiricozzi, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.636
NA - Nord America 5.149
EU - Europa 3.186
SA - Sud America 1.289
AF - Africa 243
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 3
Totale 15.530
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.898
SG - Singapore 2.888
BR - Brasile 1.050
CN - Cina 937
IT - Italia 689
VN - Vietnam 512
SE - Svezia 492
FR - Francia 394
DE - Germania 385
IE - Irlanda 324
ID - Indonesia 236
GB - Regno Unito 181
FI - Finlandia 180
IN - India 169
HK - Hong Kong 168
BD - Bangladesh 163
JP - Giappone 152
RU - Federazione Russa 151
CA - Canada 127
CI - Costa d'Avorio 116
AR - Argentina 87
IQ - Iraq 66
MX - Messico 63
ES - Italia 60
NL - Olanda 60
KR - Corea 58
PL - Polonia 53
TR - Turchia 47
EC - Ecuador 40
ZA - Sudafrica 36
AT - Austria 35
PK - Pakistan 35
SA - Arabia Saudita 34
CO - Colombia 25
CZ - Repubblica Ceca 24
MA - Marocco 24
UA - Ucraina 24
AU - Australia 23
VE - Venezuela 23
RO - Romania 22
KE - Kenya 21
CL - Cile 19
CH - Svizzera 18
JO - Giordania 17
TH - Thailandia 15
AE - Emirati Arabi Uniti 14
PE - Perù 13
PY - Paraguay 13
UZ - Uzbekistan 13
IR - Iran 12
TN - Tunisia 12
CR - Costa Rica 11
LT - Lituania 11
EG - Egitto 10
GR - Grecia 10
PT - Portogallo 10
RS - Serbia 10
BE - Belgio 9
BO - Bolivia 9
HN - Honduras 9
IL - Israele 9
MY - Malesia 9
PH - Filippine 9
JM - Giamaica 8
KZ - Kazakistan 8
NP - Nepal 8
BG - Bulgaria 7
HR - Croazia 7
HU - Ungheria 7
LB - Libano 7
TT - Trinidad e Tobago 7
TW - Taiwan 7
UY - Uruguay 7
AL - Albania 6
CY - Cipro 6
DO - Repubblica Dominicana 6
ET - Etiopia 6
PA - Panama 6
KW - Kuwait 5
MD - Moldavia 5
AZ - Azerbaigian 4
DZ - Algeria 4
GT - Guatemala 4
AO - Angola 3
BH - Bahrain 3
GE - Georgia 3
LA - Repubblica Popolare Democratica del Laos 3
MM - Myanmar 3
NG - Nigeria 3
NI - Nicaragua 3
PS - Palestinian Territory 3
QA - Qatar 3
SY - Repubblica araba siriana 3
AM - Armenia 2
BB - Barbados 2
EE - Estonia 2
EU - Europa 2
GA - Gabon 2
GY - Guiana 2
KY - Cayman, isole 2
Totale 15.503
Salva come PNG Salva come JPEG
Città #
Singapore 1.411
Ashburn 822
San Jose 679
Chandler 425
Dublin 316
Beijing 247
Jakarta 214
Lauterbourg 190
Ho Chi Minh City 178
New York 166
Hong Kong 156
Milan 154
Tukwila 154
Hefei 149
Tokyo 132
Frankfurt am Main 129
Rome 129
Helsinki 123
Hanoi 122
Abidjan 115
Bremen 115
Los Angeles 113
Moscow 105
Princeton 99
Boston 90
São Paulo 90
Dallas 83
Council Bluffs 71
Chicago 66
The Dalles 63
Santa Clara 59
Paris 58
Munich 50
Seoul 50
Kent 46
Wilmington 41
London 39
Boardman 37
Washington 37
Nuremberg 36
Atlanta 34
Montreal 34
Warsaw 34
Toronto 33
Brooklyn 31
Rio de Janeiro 31
Pune 30
San Mateo 30
Brasília 29
Amsterdam 28
Lappeenranta 28
Haiphong 26
Mexico City 26
Buffalo 25
Seattle 25
St Louis 25
Turku 25
Stockholm 24
Belo Horizonte 23
Da Nang 23
Denver 23
Shanghai 22
Curitiba 21
Hyderabad 21
Chennai 20
Dhaka 20
Vienna 20
Houston 19
Johannesburg 19
Orem 19
Baghdad 18
Brno 18
Nairobi 18
North Bergen 17
Amman 16
Hangzhou 16
Phoenix 16
Manchester 15
Guarulhos 14
Guayaquil 14
Memphis 14
Porto Alegre 14
Redwood City 14
Roubaix 14
San Francisco 14
Ankara 13
Dearborn 13
Jeddah 13
Naples 13
Riyadh 13
Düsseldorf 12
Mumbai 12
Ottawa 12
Santiago 12
Tashkent 12
Cleveland 11
Guangzhou 11
Poplar 11
Recife 11
Salvador 11
Totale 8.539
Salva come PNG Salva come JPEG
Nome #
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study 473
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study 238
Clinical and ultrasonographic profile of adalimumab-treated hidradenitis suppurativa patients: A real-life monocentric experience 166
Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: A multicenter retrospective study 145
Case report: Dupilumab treatment improved type 2 disorders in a patient with IPEX syndrome diagnosis 139
Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study 131
Drug survival of biologics and non-biologics in patients affected by palmoplantar psoriasis: a “real-world”, mono-center experience 128
Assessment of alopecia areata universalis successfully treated with upadacitinib 125
Clinical, epidemiological, and therapeutic hallmarks of pyoderma gangrenosum: a case series of 35 patients 124
Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis 124
Therapeutic impact and management of persistent head and neck atopic dermatitis in dupilumab-treated patients 124
Similar Levels of Efficacy of Two Different Maintenance Doses of Adalimumab on Clinical Severity and Quality of Life of Patients with Hidradenitis Suppurativa 119
Periocular molluscum contagiosum in an atopic dermatitis patient treated with upadacitinib 118
Dupilumab-associated ocular adverse events are predicted by low tear break-up time and correlate with high IL-33 tear concentrations in patients with atopic dermatitis 116
The preclinical discovery and development of deucravacitinib for the treatment of psoriasis 116
Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis 114
Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study 114
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 114
Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy 114
Dupilumab improves clinical manifestations, symptoms and quality of life in adult patients with chronic nodular prurigo 113
Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience 112
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis 112
Pediatric Hidradenitis Suppurativa: A Cross-Sectional Study on Clinical Features and Treatment Approaches 112
Biological agents targeting interleukin-13 for atopic dermatitis 112
Baricitinib: therapeutic potential for moderate to severe atopic dermatitis 111
Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis 111
Evaluation of Upadacitinib efficacy in the treatment of Atopic Dermatitis of sensitive areas 110
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study 109
Novel Therapeutic Strategies in the Topical Treatment of Atopic Dermatitis 108
Improvement of severe facial seborrheic dermatitis following low-dose isotretinoin therapy 107
Topical treatment of severe xerosis: Results of an observational study 106
A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis 106
Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments 105
Real-Time Confocal Imaging for Hidradenitis Suppurativa: Description of Morphological Aspects and Focus on the Role of Follicular Ostia 105
New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis 103
Histological features of immune cell infiltrate in lesional skin correlate with therapeutic response to dupilumab 102
Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation 102
Overview of Atopic Dermatitis in Different Ethnic Groups 101
Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study 101
Evaluation of the Impact of Night Shift Work on Disease Severity in Psoriatic Patients: A Case-Control Study with Clinical, Hormonal, and Immunological Evaluation 101
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis 101
Flares as dynamic predictive factor of response to adalimumab in hidradenitis suppurativa: real-life data 100
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era 99
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 99
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry 98
Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience 98
Characterization of comorbid conditions burdening hidradenitis suppurativa: A multicentric observational study 98
A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis 97
Successful response of upadacitinib in different clinical phenotypes of atopic dermatitis 97
Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment 96
Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study 96
COVID-19 hygiene measures: hand eczema and insights into ACE2 and integrins as key molecules for SARS-CoV-2 cutaneous transmission 96
Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study 96
Gianotti-Crosti Syndrome after SARS-CoV-2 infection 95
Investigational systemic drugs for moderate to severe plaque psoriasis: What's new? 95
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations 95
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 94
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 94
TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand 94
Real-Time Confocal Imaging for Hidradenitis Suppurativa: Description of Morphological Aspects and Focus on the Role of Follicular Ostia 94
COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus 92
Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study 90
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study 90
European consensus statement on phenotypes of pustular psoriasis 88
Long-Term Real-World Safety Profile of Secukinumab Assessed Through a 9-Year Experience in Patients Affected by Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Results From a Multicentric Retrospective Study 87
Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study 87
Low grade of satisfaction related to the use of current systemic therapies among pustular psoriasis patients: a therapeutic unmet need to be fulfilled 86
Drug survival of methotrexate and predictor factors for discontinuation in psoriasis 86
Hidradenitis Suppurativa Associated with Down Syndrome Is Characterized by Early Age at Diagnosis 86
Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study 86
Immune response to vaccination in patients with psoriasis treated with systemic therapies 85
Successful response to upadacitinib in the treatment of atopic dermatitis lesions involving sensitive and visible areas resistant to dupilumab treatment 84
Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study 84
AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa 84
Creation of a severity index for hidradenitis suppurativa that includes a validated quality-of-life measure: the HIDRAscore 84
Long-term management of moderate-to-severe adult atopic dermatitis: A consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA), and the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC) 84
The psychological burden during COVID-19 pandemic in a cohort of patients affected by moderate-to-severe atopic dermatitis treated with dupilumab 83
Optimizing acitretin use in patients with plaque psoriasis 83
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis 83
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic 83
Factors related to the onset and recurrence of flares in hidradenitis suppurativa patients treated with adalimumab 83
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year 82
Testing biologics and intracellular signaling inhibitors on pediatric atopic dermatitis: a stairway to modern therapeutic approaches 82
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis 81
The role of insomnia in the vulnerability to depressive and anxiety symptoms in atopic dermatitis adult patients 79
Current therapeutic paradigm in pediatric atopic dermatitis: Practical guidance from a national expert panel 79
Infectious adverse events in patients with atopic dermatitis treated with baricitinib 78
The risk of covid-19 pandemic in patients with moderate to severe plaque psoriasis receiving systemic treatments 77
Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema (TREAT) Registry Taskforce 76
Successful treatment with secukinumab in an HIV-positive psoriatic patient after failure of apremilast 76
Immunologic biomarkers for clinical and therapeutic management of psoriasis 76
Successful use of anti‐IL‐23 molecules in overweight‐to‐obese psoriatic patients: a multicentric retrospective study 74
The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies 74
Alexithymia affects patients with hidradenitis suppurativa 74
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement 74
Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study 73
Spotlight on dupilumab in the treatment of atopic dermatitis: Design, development, and potential place in therapy 73
Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study 73
Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study 72
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study 71
Totale 10.265
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.576
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.576
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022466 47 2 13 11 17 4 8 45 20 96 91 112
2022/20231.894 152 189 143 311 100 235 150 176 233 61 103 41
2023/20241.859 45 374 116 272 85 252 121 90 39 93 147 225
2024/20252.959 60 40 286 66 283 129 92 93 492 251 597 570
2025/20268.144 1.291 202 591 941 1.042 331 1.480 413 452 541 481 379
2026/2027225 225 0 0 0 0 0 0 0 0 0 0 0
Totale 15.778